Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
Clinical Trial Information
Trial Contact: Armatti, Julie M; Parker, Melanie; Frankos, Marie; Jones, Jamie; Singh, Sarah H
Trial Phone: 321-843-5284 ; 321-843-1036 ; 321-842-8738 ; 3218412008 ; 321.841.7561
-
IRB No: 23.112.06
Protocol Abbrev: SJiMB21
Principal Investigator:
Phase: Drug: Phase II
Age Group: Pediatric
ClinicalTrials.gov ID: NCT05535166
-
Objective
to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma
